Management of HR-Positive, HER2-Negative Advanced Breast Cancer with CDK4/6 Inhibitors: Effect of Online Education on Clinician Knowledge, Competence, and Confidence

G. FISHER, Medscape, Global Education; London, United Kingdom; D. MIDDLETON, Medscape, Global Education; New York, USA; C. DAY, Medscape, Global Education; London, United Kingdom; A. DI LEAO, Hospital di Pisa, Istituto Toscana Tumor; Sandro Pignatelli Medical Oncology Unit, Pisa, Italy

BACKGROUND

This study determined whether online continuing medical education could improve knowledge and competence of oncologists and obstetricians/gynecologists in the treatment of advanced breast cancer.

RESULTS

**QUESTION 1 RESULTS**

- **Oncologists (n = 69)**
  - Pre-assessment: 16% correct
  - Post-assessment: 83% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .487)

- **Obstetricians and Gynecologists (n = 41)**
  - Pre-assessment: 17% correct
  - Post-assessment: 85% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .561)

**QUESTION 2 RESULTS**

- **Oncologists (n = 69)**
  - Pre-assessment: 10% correct
  - Post-assessment: 78% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .411)

- **Obstetricians and Gynecologists (n = 41)**
  - Pre-assessment: 18% correct
  - Post-assessment: 82% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .429)

**QUESTION 3 RESULTS**

- **Oncologists (n = 69)**
  - Pre-assessment: 1% correct
  - Post-assessment: 95% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .556)

- **Obstetricians and Gynecologists (n = 41)**
  - Pre-assessment: 4% correct
  - Post-assessment: 90% correct
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .597)

**SELF-EFFICACY RESULTS**

- **Oncologists (n = 69)**
  - Pre-assessment: 105%
  - Post-assessment: 44%
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .486)

- **Obstetricians and Gynecologists (n = 41)**
  - Pre-assessment: 105%
  - Post-assessment: 83%
  - *Denotes a statistically significant change from pre- to post-assessment (P < .001; V = .486)

METHODS

A 15-minute, online case-based video activity was launched for evaluation outside the USA in December 2016, with data collected until January 2017. The activity consisted of video vignettes for simulated behavior modeling using realistic patient/clinician interactions interspersed with guidance from an expert faculty. The patient was postmenopausal, with a recurrence of HR-positive/HER2-negative advanced breast cancer following completion of standard endocrine therapy 3 years earlier.

The patient is a 58-year-old postmenopausal woman who was diagnosed with ER-positive/HER2-negative, anastrozole, now 2 years after ending adjuvant therapy, Mrs Burns appears to have a recurrence of her cancer. She has 2 new lesions in her liver and enlarged left supraclavicular nodes. Which of the following treatment options would you recommend? (Correct Answer: Palbociclib plus letrozole) She has 2 new lesions in her liver and 2 enlarged left supraclavicular nodes. Which of the following treatment options would you recommend? (Correct Answer: Palbociclib plus letrozole) She has 2 new lesions in her liver and 2 enlarged left supraclavicular nodes. Which of the following treatment options would you recommend? (Correct Answer: Palbociclib plus letrozole) She has 2 new lesions in her liver and 2 enlarged left supraclavicular nodes. Which of the following treatment options would you recommend? (Correct Answer: Palbociclib plus letrozole) She has 2 new lesions in her liver and 2 enlarged left supraclavicular nodes. Which of the following treatment options would you recommend? (Correct Answer: Palbociclib plus letrozole)

CONCLUSION

These improvements are expected to facilitate clinical application of CDK4/6 inhibitors in practice.